Ecdysone-based system for controlled inducible expression of metabotropic glutamate receptor subtypes 2, 5  and 8 by Downey, P. M. et al.
10.1177/1087057105280285Downey et al.Inducible Expression of Metabotropic Glutamate Receptors
Ecdysone-Based System for Controlled Inducible Expression
of Metabotropic Glutamate Receptor Subtypes 2, 5, and 8
PATRICK. M. DOWNEY, GIANLUCA LOZZA, ROBERTA PETRÒ, ENRICA DIODATO,
CHIARA FOGLIA, FEDERICA BOTTAZZOLI, ROSSELLA BRUSA, TATIANA ASQUINI,
ANGELO REGGIANI, and MARIAGRAZIA GRILLI
Stable and inducible expression of human metabotropic glutamate receptor types 2, 5, and 8 was achieved in HEK293 cells
using the ecdysone inducible system. Treatment of the respective cell lines with ponasterone A resulted in time- and concen-
tration-dependent induction of receptor expression. In all cases, the functional activation of receptors was determined by mea-
suring increases in intracellular calcium. The physiologically Gαi-coupled receptors mGluR2 and mGluR8 were successfully
coupled to phospholipase C activation using the chimeric G protein Gαq/o. The pharmacological properties of recombinant re-
ceptors were characterized and proved to be similar to native receptors. Our data suggest that the ecdysone system has a num-
ber of characteristics that make it well suited for expressing mGluRs and that the combined use of this system and chimeric G
proteins allows receptors to be characterized using a rapid and straightforward Ca2+ assay. (Journal of Biomolecular Screening
2005:841-848)
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INTRODUCTION
GLUTAMATE IS GENERALLY RECOGNIZED as being the most im-portant excitatory neurotransmitter in the mammalian CNS.
It is intimately involved in a wide range of neuronal and glial pro-
cesses, by the activation of both ionotropic and metabotropic
(mGluR) receptor subtypes.1 These latter receptors are G protein–
coupled receptors (GPCRs) and belong to a group of receptors that
includes the Ca2+ sensing receptor, the GABAB receptors, and a
large number of putative olfactory, pheromone, and taste recep-
tors.2 The mGlu receptors are widely distributed throughout the
CNS, and there is now substantial evidence for an important role of
mGluRs in normal brain functions as well as in neurological and
psychiatric disorders.
The metabotropic glutamate receptors form a family of 8 sub-
types that are subdivided into 3 groups based on their sequence
homology, pharmacology, and transduction mechanisms. Group I
receptors (mGluR1 and mGluR5) couple through Gαq/11 proteins
to the activation of phospholipase C, resulting in phosphoinositide
hydrolysis, the release of calcium from intracellular stores and the
activation of protein kinase C. Groups II (mGluR2 and mGluR3)
and III (mGluR4, mGluR6, mGluR7, and mGluR8) are negatively
coupled to adenyl cyclase (AC) through Gαi/Gαo proteins, thereby
inhibiting cyclic AMP (cAMP) formation and cAMP-dependent
protein kinase activation.3 Group I receptors usually act
postsynaptically to increase neuronal excitability, whereas the
group II and III receptors most often act presynaptically to reduce
neurotransmitter release, including glutamate.4 Excessive
glutamatergic neurotransmission has been shown to underlie many
CNS diseases and to play an important role in the pathophysiology
of diseases such as depression, anxiety, and chronic pain, which
represent key areas of interest for drug development. Accordingly,
mGluR group I antagonists or group II/III agonists could represent
useful agents for the treatment of these conditions. Indeed, group I
antagonists have been shown to possess antidepressant activity in
preclinical models5 and to be very effective agents in the treatment
of prolonged and chronic pain.6-8 Studies using specific group II
agonists suggest that such compounds may be useful in the treat-
ment of inflammatory pain,9,10 chronic pain,11 and anxiety.12 Less is
known about the role of group III mGluRs, principally due to the
lack of potent and selective ligands. However, studies using knock-
out mice show that animals lacking mGluR8 display a marked in-
crease in anxiety-related behavior, possibly suggesting that
mGluR8 agonists may also produce anxiolysis.13 In support of this
notion, specific group III agonists have recently been shown to
produce anxiolytic and antidepressant-like effects.14 The
metabotropic glutamate receptors thus represent a potential
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goldmine of drug targets for the treatment of many CNS disorders,
and their involvement in depression, anxiety and chronic pain
makes them particularly appealing targets.
An important prerequisite in the search for selective mGluR
modulators is the development of specific clonal cell lines for each
receptor type. This has become even more important since the dis-
covery of allosteric modulatory sites located in the 7 TM region of
mGluRs. These sites are less conserved among groups and sub-
types and thus make it possible to identify new chemical entities
with improved selectivity within the family of metabotropic gluta-
mate receptors. Functional cell-based assays for single mGluRs
permit chemical libraries to be screened in the search for potent
agonists and antagonists as well as the more selective allosteric
modulators.
One of the problems in isolating cell lines that express gluta-
mate receptors is the fact that glutamate is released from cells into
the culture medium and hence causes desensitization and/or down-
regulation of the receptor.15 To circumvent this problem, we used
an inducible system, the ecdysone system. This system is based on
the ability of ecdysone, an insect steroid, to potently induce tran-
scription via the activation of a heterodimeric receptor composed
of the ecdysone receptor (EcR) and the ultraspiracle protein
(USP).16 Responsiveness to ecdysone in mammalian cells is recre-
ated by transfection of EcR, the retinoid X receptor (RxR; the
mammalian homologue of USP), an ecdysone-responsive re-
porter, and application of ecdysone or a synthetic analogue such as
ponasterone A. Expression of a given cDNA can be placed under
the control of the EcR/RxR heterodimer, which activates transcrip-
tion in the presence of the exogenous inducing agent. Our results
suggest that this system is very well suited to the development of
functional mGluR receptor assays and, in combination with the
use of chimeric Gαq/o proteins, allows the use of a single assay
platform to analyze all receptor types.
MATERIALS AND METHODS
Molecular biology
cDNA was synthesized from human hippocampal mRNA
(Clontech, Mountain View, CA) using the superscript kit accord-
ing to the manufacturer’s (Invitrogen, Paisley, UK) instructions.
The coding sequences of mGluR2 and mGluR5b were amplified
from hippocampal cDNA by PCR using a proofreading enzyme
PfuTurbo (Stratagene, La Jolla, CA). A plasmid pCMV6-XL5-
mGluR8 encoding the human mGluR8a cDNA was acquired from
Origene (Rockville, MD), and the hmGluR8a coding sequence
was amplified from this plasmid by PCR. All amplified products
were completely sequenced on both DNA strands to make sure that
sequence errors had not been introduced in the amplification pro-
cess. The mGluR coding sequences were subcloned into the ex-
pression vector pIND (Invitrogen) using appropriate restriction
enzymes. A chimeric G protein Gαq/o constructed by replacing the
last 5 amino acids of the Gαq alpha subunit with those of the Gαo
protein as previously described17 was a kind gift of Dr. F. Monsma
(Schering-Plough Research Institute, Kenilworth, NJ). The chime-
ric Gαq/o coding sequence was subcloned into pCDNA3-Hygro us-
ing appropriate restriction enzymes. A pIND vector expressing
mGluR8a and the Gαq/o as a single transcript was constructed by
inserting an IRES sequence between mGluR8a and Gαq/o. The
pIRESneo2 vector plasmid (Clontech) was digested with XhoI and
SmaI to remove the Neor coding sequence and polyA sequence;
they were replaced by Gαq/o cDNA, obtained from a pCDNA3.1-
Gαq/o plasmid through XhoI-SmaI cleavage. Then, the IRES-Gαq/o
cassette was subcloned into a pIND-mGluR8a plasmid as a NotI
fragment, just downstream from the receptor cDNA previously
cloned into pIND as a HindIII-NotI fragment. The mGluR5b
and mGluR8a sequences were identical to those previously re-
ported,18,19 whereas the amplified mGluR2 cDNA was identical to
the variant reported by Kowal and others.20
Isolation of clonal cell lines
The HEK-293EcR cell line (Invitrogen), stably expressing the
heterodimeric ecdysone receptor from the pVgRXR plasmid, was
maintained in DMEM high-glucose medium, supplemented with
10% fetal bovine serum (FBS), 10,000 U/mL penicillin, 10 mg/
mL streptomycin, 2 mM GlutaMAX™ (Invitrogen), and 400 µg/
mL Zeocin™ (Invitrogen) at 37° C, in an atmosphere contain-
ing 5% CO2. Stable transfections with mGluRs and chimeric G
protein–coding vectors were performed using calcium phosphate
according to standard protocols. Stably transfected clones were
obtained after selection with 550 µg/mL Geneticin® (Invitrogen)
(mGluR5b and mGluR8a-Gαq/o cell lines) and 550 µg/mL
Geneticin® (Invitrogen) and 200 µg/mL hygromycin B (mGluR2-
Gαq/o cell line). All cell culture media and reagents were from
Invitrogen (Paisley, UK). The sensitivity to DMSO was tested for
all cell lines; no signs of toxicity were observed when DMSO was
added up to a final concentration of 1%.
Western blotting
Cells were plated in 6-well dishes in complete DMEM and in-
duced by adding various amounts of a 1 mM stock of ponasterone
A (Invitrogen). Ponasterone A was dissolved in 100% ethanol, and
ethanol levels were compensated in all induced cultures. After a
24-h induction period, cells were washed with ice-cold phosphate-
buffered saline, detached from the dishes using a scraper, and re-
suspended in lysis buffer (NaCl 150 mM, Tris-HCl 50 mM, Triton
1%, NP40 1%, SDS 0.2%, EDTA 2 mM, PMSF 1 mM, NaF 50
mM, and protease inhibitors). Samples were collected on ice and
centrifuged at 10,000g for 15 min at 4° C and were subsequently
stored at –80° C. Immunoblotting was performed using a poly-
clonal anti-mGluR5 antibody (Upstate, Waltham, MA) 0.5 µg/mL
and a monoclonal anti-GAPDH antibody (Chemicon, Temecula,
CA) 1 µg/mL, following standard procedures.
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Measurement of intracellular calcium transients
Cells from clonal cell lines were seeded into black, clear-
bottom, 96-well plates at a density of 60,000 cells/well, in DMEM
high glucose supplemented with 5% dialysed FBS, 3 U/mL
glutamic-pyruvic transaminase (Sigma, St. Louis, MO), 5 mM so-
dium pyruvate, 5 µM ponasterone A. Following 24-h incubation,
the cells were loaded with a fluorescent calcium indicator, either
Calcium 3® or FLIPR® calcium assay kit, both supplied by Molec-
ular Devices (Sunnyvale, CA). The dyes were dissolved in the as-
say buffer, which consisted of Hanks’ balanced salt solution
(HBSS; Gibco Life Technologies, Carlsbad, CA) buffered with 20
mM Hepes solution (Sigma). To avoid dye bleaching, 2.5 mM
probenecid (Sigma) was added to the calcium indicator solution.
Cells were loaded with the dye for 2 h at 37° C in a CO2 incubator.
A fluorometric imaging plate reader (FLIPR 384; Molecular De-
vices) was used to measure intracellular calcium by increases in
fluorescence upon agonist stimulation following 30-s baseline
measurement or 10 min antagonist administration.
Compounds
Agonists. (1S,3R-ACPD), 1-aminocyclopentane-1S,3R-dicar-
boxylic acid; (2R,4R-APDC), (2R,4R)-4-aminopyrrolidine-2,4-
dicarboxylic acid; (L-AP4), L(+)-2-amino-4-phosphono butyric
acid; (L-CCG 1), (2S,3S,4S)-α-(carboxycyclopropyl) glycine;
(CHPG), (RS)-2-Chloro-5-hydroxyphenylglycine; (DCG-IV),
(2S2′R,3′R)-2-(2′3′-dicarboxycyclopropyl) glycine; (DCPG),
(S)-3-4-Dicarboxyphenylglycine; (DHPG), 3,5-dihydro-
phenylglycine; L-Glutamate; (NAAG), N-acetylaspartyl-
glutamate; (PPG), (R,S)-4-phosphonophenylglycine; quisqualic
acid.
Antagonists. (LY341495), (2S)-2-Amino-2-[(1S,2S)-2-
carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid; (MPEP),
Methylphenylethynylpyridine; (MTEP) 3-[(2-methyl-1,3-thiazol-
4-yl)ethyl]pyridine.
All agonists and antagonists were purchased from Tocris
Cookson (Bristol, UK). Compounds were dissolved in HBSS or
DMSO depending on their solubility. The final concentration of
DMSO in all samples was compensated.
Data analysis
EC50/IC50 values were determined by nonlinear regression anal-
ysis using the software Prism 4.0 (Graphpad, San Diego, CA).
Data were fitted as sigmoidal concentration-response curves and
analyzed by a 4-parameter logistic equation. The Z′ factor,21 a di-
rect measure of assay quality, was measured using the following
equation:
′ = −
+
−
+
+
−
−
Z c c
c c
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where σc+ and σc– are the standard deviations of positive and nega-
tive control samples, respectively, and µc+ and µc– are the means of
positive and negative controls, respectively. We tested the robust-
ness of our mGluR5 assay in its ability to demonstrate both
agonism and antagonism. Calculating the Z′ in the agonism assay,
the positive control was vehicle + quisqualate (100 nM), whereas
the negative control was vehicle only. We used 48 wells of a 96-
well plate for the positive and negative controls, respectively, with
3 replicate plates per day, and we performed the assay on 3 consec-
utive days. In determining the Z′ for the antagonism assay, we used
a similar protocol but used vehicle + quisqualate (100 nM) as the
positive control and vehicle + MPEP (50 nM) + quisqualate (100
nM) as the negative control; again, we used 3 half-plates for posi-
tive and negative controls, respectively, with 3 replicate plates per
day, and we performed the assay over 3 consecutive days. The final
Z′ for the assay is the average of the antagonism and agonism
determinations.
RESULTS
The ecdysone system was used to establish heterologous induc-
ible expression of representative mGlu receptors from all 3 groups,
mGluR5b (group I), mGluR2 (group II), and mGluR8a (group III).
In this system, transgene expression is under the control of a mini-
mal heat shock promoter, which contains 5 copies of the ecdysone/
glucocorticoid responsive element (5X E/GRE).16 The level of
transcription of the gene of interest can be simply modulated by the
addition of the inducer ponasterone A, a synthetic analogue of
ecdysone. Optimal 293EcR clonal cell lines expressing each mGlu
receptor were obtained and pharmacologically and biochemically
characterized.
mGluR5 inducible cell line
mGluR5b is a Gαq-coupled receptor; its activation thus leads to
an increase in intracellular calcium, which can be measured using a
FLIPR. Clonal cell lines expressing mGluR5 were initially
prescreened for the stimulation of calcium mobilization in re-
sponse to quisqualate following 24-h induction with 5 µM
ponasterone A. A single clonal cell line referred to as 2A4 was cho-
sen for further study. To determine how receptor density can be
modulated in this system, cells were induced for 24 h with increas-
ing concentrations (1, 3, and 5 µM) of ponasterone A, and mGluR5
protein immunoreactivity was determined by Western blotting.
The mGluR5 protein could not be detected in uninduced cells,
indicating near total absence of transcription, but it is visible after
incubation with 1 µM ponasterone A, and the amount of immuno-
reactive signal progressively increases with increasing concentra-
tions of inducer (see Fig. 1, inset). The functional coupling of the
receptor was tested by measuring quisqualate-induced Cai2+ mobi-
lization after ponasterone A induction. As shown in Figure 1,
quisqualate (0.001-3 µM) elicited a concentration-dependent in-
crease in Cai2+, with maximal changes in relative fluorescence
units (RFUs) of 8100 ± 210, 10,200 ± 47, and 11,700 ± 308 (n = 3)
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after 1, 3, and 5 µM ponasterone, respectively. Corresponding ago-
nist EC50 (log M) values of –7.38 at 1 µM, –7.40 at 3 µM, and –7.51
at 5 µM inducer concentration were obtained. In the absence of in-
duction by ponasterone A, no significant functional response was
detected following quisqualate stimulation, indicating tight regu-
lation of recombinant receptor expression. A small amount of sig-
nal was noted, however, at higher quisqualate concentrations; we
believe that this is probably due to a low level of unregulated tran-
scription as no signal was observed in our nontransfected cell lines
when challenged with equivalent concentrations of quisqualate.
A detailed characterization of the pharmacological properties
of the hmGluR5b receptor was undertaken using reference
agonists and antagonists. As shown in Figure 2a, all characterized
agonists were highly efficacious, eliciting maximum responses
comparable to those observed with the endogenous agonist L-
glutamate. The rank order of agonist potency for examined com-
pounds was quisqualate > L-glutamate > DHPG > 1S-3R-ACPD >
CHPG, in agreement with that determined for the native rat recep-
tor22 and the recombinant human receptor.23 EC50 values were cal-
culated as reported in Table 1. To examine the effect of antagonists,
cells were pretreated with the noncompetitive mGluR5 selective
antagonists MPEP and MTEP and the competitive antagonist LY
341495. All antagonists produced a concentration-dependent inhi-
bition of quisqualate-induced calcium mobilization, as shown in
Figure 2b. The following rank order of potency was determined:
MPEP > MTEP > LY341495; IC50 values were calculated against
an EC80 concentration of quisqualate and are reported in Table 1.
Calcium-coupled group II and III inducible cell lines
To use intracellular calcium transients as an assay readout for
group II and III receptors, we cotransfected hmGluR2 and
hmGluR8a receptors with the chimeric G protein Gαq/o, which has
been shown to effectively couple with all Gαi/o-coupled mGlu re-
ceptors, at least in transient transfections.24,25 Because stable
overexpression of the chimeric Gαq/o protein could potentially
cause alterations in normal cell physiology, we tried 2 different ex-
perimental approaches. In our mGluR2 cell line, we constitutively
expressed the chimeric G protein but kept the metabotropic recep-
tor under the control of the inducible promoter, whereas with our
mGluR8 cell line, both receptor and G protein were inducible. In
the latter case, inducible expression of both the mGlu receptor and
chimeric G protein was achieved by inserting an IRES sequence
between the receptor and the G protein coding sequences, thus en-
suring that they were expressed as a single transcript under the
control of the inducible promoter.
mGluR2-inducible cell line
Following cotransfection of mGluR2 and Gαq/o, clonal cell
lines were prescreened for DCG-IV-induced Cai2+ mobilization
following induction with ponasterone A (5 µM). A single clone,
referred to as 2q/o, which revealed agonist-dependent Cai2+ mobi-
lization when induced with negligible background levels in the ab-
sence of induction, was expanded and characterized further. Clone
2q/o gave very robust calcium signals, with maximal changes
in RFUs in response to DCG-IV of up to 45,000 and a calculated
EC50 value of 130 nM. This cell line showed excellent signal-to-
Downey et al.
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FIG. 1. Concentration response curves (mean ± SEM, n = 3) for the ef-
fect of quisqualate on calcium mobilization assay using 293EcR cells ex-
pressing mGluR5b without induction () and induced with 1 µM (), 3
µM (), and 5 µM () concentrations of ponasterone A. The inset shows
Western blot analysis, displaying the extent of immunoreactive mGluR5b
protein 24 h after induction with 0, 1, 3, and 5 µM concentrations of
ponasterone A.
Table 1. Functional Activities of Agonists and Antagonists
Examined in 293EcR Cell Lines 2q/o, 2A4, and 8q/o Expressing
mGluR2, mGluR5, and mGluR8, Respectively
EC50 µM
Agonist mGluR2 mGluR5 mGluR8
L-glutamate 1.6 (1.1-2.4) 1.5 (1.1-2.2) 8.8 (5.8-11)
Quisqualate >1000 0.03 (0.02-0.05) >1000
DHPG 4.2 (2.8-5.7)
DCG-IV 0.13 (0.08-0.18)
1S,3R-ACPD 3.1 (2.2-4.2) 15.7 (11.6-21.2)
2R,4R-APDC 1.3 (0.9-1.8)
L-CCG I 0.14 (0.08-0.2) 2.8 (1.6-4.9)
L-AP4 1.6 (0.9-2.9)
PPG 4.7 (2.7- 8.1)
DCPG 0.8 (0.4-1.6)
NAAG >1000
IC50 µM at IC50 µM at IC50 µM at
Antagonist 300nM DCG-IV 100 nM Quisqualate 14 µM Glutamate
MPEP >100 0.02 (0.01-0.03) >100
MTEP 0.09 (0.06-0.14)
LY341495 0.0012 (0.0009-0.0015) 35.3 (22.4-48.2) 0.13 (0.08-0.16)
A description of the abbreviations used for all agonists and antagonists can be found in the
Materials and Methods section under Compounds. Data are the mean EC50 values of
agonists and IC50 values of antagonists determined from 3 independent experiments per-
formed in quadruplicate. Values are given with corresponding 95% confidence limits. Each
dose-response curve consisted of 8 different drug concentrations. All antagonist IC50
values were determined at agonist concentrations corresponding to the EC80 of the spe-
cific agonist, 300 nM DCG-IV for mGluR2, 100 nM quisqualate for mGluR5, and 14 µM
L-glutamate for mGluR8.
background ratio, as no significant DCG-IV-stimulated calcium
responses were detected in uninduced cells, as shown in the inset in
Figure 3. To show that the pharmacology of the receptor is unal-
tered in this system where the receptor couples through an exoge-
nous chimeric G protein, mGluR2-coupled calcium signaling was
measured in response to a number of reference agonists for
metabotropic glutamate receptors. As shown in Figure 3, the group
II selective agonist DCG-IV as well as all the group II preferred
agonists including L-CCG-I, 2R,4R-APDC, and 1S,3R-APDC
were highly efficacious, eliciting maximum responses comparable
to those observed with the endogenous agonist L-glutamate. In
contrast, the addition of the group I agonist quisqualate or the
mGluR3-specific agonist NAAG did not elicit an increase in
intracellular calcium. The rank order of agonist potency in the re-
combinant cell line expressing hmGluR2 and the chimeric Gαq/o
protein was DCG-IV ~ L-CCG-I > L-glutamate ~ 2R,4R-APDC >
1S,3R-APDC. Calculated EC50 values for each agonist at the re-
combinant hmGluR2 receptor are summarized in Table 1. These
data are in agreement with previous work undertaken on the native
rat receptor26 as well as the physiologically coupled recombinant
hmGluR2 where cAMP or GTPγS assays were used.20,27 We also
tested the reference compound LY341495, which acts as an antag-
onist at all mGluRs but has the highest affinity for the group II re-
ceptors. The compound tested in the presence of an EC80 concen-
tration of DCG-IV resulted in a concentration-dependent
inhibition of agonist-induced Cai2+ mobilization, as shown in
Figure 4, giving an estimated IC50 of 1.2 nM.
mGluR8-inducible cell line
Following transfection of the 293EcR cell line with the induc-
ible mGluR8a-Gq/o construct, clonal cell lines were isolated and
characterized for L-glutamate-dependent Cai2+ mobilization after
induction with 5 µM ponasterone A. A single clone referred to as
8q/o was chosen for further studies. When induced, clone 8q/o
gave robust concentration-dependent intracellular calcium in-
creases after being stimulated with L-glutamate and undetectable
agonist-induced signal in the absence of induction (Fig. 5, inset). A
detailed pharmacological analysis was performed on the recombi-
nant cell line using a number of well-characterized agonists, and
the rank order of potency was determined as DCGP > L-AP4 > L-
CCG-I > PPG>L-glutamate, as depicted in a representative experi-
Inducible Expression of Metabotropic Glutamate Receptors
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FIG. 2. (a) Effect of various agonists on Ca2+ mobilization in cell line
2A4 expressing mGluR5b. Agonists are quisqualate (), L-glutamate (),
DHPG (), 1S,3R-ACPD () and CHPG (). Values are means ± SEM
of quadruplicate determinations from a typical experiment. (b) Antago-
nism by MPEP (), MTEP (), and LY341495 () of the agonist-stimu-
lated calcium mobilization in the mGluR5b expressing cell line 2A4.
Cells were pretreated for 10 min with the various antagonists over the indi-
cated concentration ranges before a challenge with an EC80 (100 nM) con-
centration of quisqualate. Inhibition curves were constructed from the per-
centage responses pooled from 3 independent experiments performed in
quadruplicate. Values are means ± SEM.
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FIG. 3. Effect of various agonists on Ca2+ mobilization in cell line 2q/o
expressing mGluR2 and the chimeric G protein Gαq/o. Agonists are 
DCG-IV (group II selective), L-CCGI (group II preferred), L-gluta-
mate,2R,4R-APDC (group II preferred),1S,3R-ACPD (group II pre-
ferred),  NAAG (mGluR3 selective), and  quisqualate (group I selec-
tive). Values are means ± SEM of quadruplicate determinations from a
typical experiment. Inset concentration-response curves (mean ± SEM,
n = 3) for the effect of DCG-IV on calcium mobilization using cell line 2q/
o expressing mGluR2 and the chimeric G protein Gαq/o, pretreated for 24 h
in the absence (  or presence  of ponasterone A (5 µM).
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ment in Figure 5. These results are in agreement with data obtained
from hmGluR8a-expressing cell lines using cAMP assays19,28 or
radioligand binding assays.29 Agonist EC50 values for our
hmGluR8a-expressing cell line were calculated and are summa-
rized in Table 1. L-glutamate-induced Cai2+ release was tested in
the presence of the competitive antagonist LY341495. When an
agonist concentration corresponding to an EC80 value was used to
stimulate the receptor, addition of the reference antagonist resulted
in a concentration-dependent inhibition of glutamate-elicited cal-
cium signal with a calculated IC50 of 130 nM. As expected,
LY341495 was more potent on hmGluR2 than hmGluR8 (Fig. 4).
Inducible cell line stability and assay reproducibility
To test the functional stability of the mGluR-expressing induc-
ible cell lines, the biological response and the pharmacological
properties of the recombinant receptors were tested at increasing
passage number. We tested cell lines up to 30 passages, and no sig-
nificant changes in the efficacy or potency of agonists to induce
Cai2+ mobilization after ponasterone A induction was observed. In
addition, no significant response to agonists in uninduced cells was
shown with increasing passage number. To determine the robust-
ness of the assay, we determined the Z′ for the mGluR5 cell line
2A4; this was calculated as 0.7, showing that the assay is very re-
producible. The ecdysone-inducible system would thus appear to
be sufficiently robust to allow it to be used in screening assays in
which very high reproducibility is essential.
DISCUSSION
Pharmacologically active compounds that are able to modulate
the activity of a specific metabotropic glutamate receptor subtype
may be effective in the treatment of a wide range of CNS diseases.
However, it has been traditionally very difficult to find small mole-
cules acting at the agonist-binding site that achieve true subtype se-
lectivity. The generation of high-throughput screening has made it
possible to search for compounds that interact with allosteric sites
rather than the historically targeted orthosteric site. The first such
compounds described for the mGluRs were MPEP and CPCCOet,
which are negative allosteric modulators selective for mGluR5 and
mGluR1, respectively.30,31 Recently, positive allosteric modulators
selective for mGluR1, mGluR2, mGluR4, and mGluR5 have also
been described.32-35 The availability of functional cell-based assays
for all members of the mGluR family makes it possible to screen
chemical libraries in the search for potent agonists, antagonists,
and allosteric modulators. Equally important, clonal cell lines can
be used to counterscreen active compounds to determine if their
activities are indeed receptor specific. This is particularly impor-
tant since the revelation that the noncompetitive mGluR5 antago-
nist MPEP also acts as a positive modulator of mGluR436 and the
discovery of PHCCC, a compound highly related to CPCCOet that
predominantly acts as a positive modulator of mGluR4 but is also a
noncompetitive inhibitor of mGluR1.34
We have used the ecdysone system to functionally express the
Gαq coupled mGluR5 and in combination with the chimeric Gαq/o
protein to functionally express mGluR2 and mGluR8. In all of our
cell-based assays, the receptors displayed a pharmacological pro-
file for both agonists and antagonists that faithfully represented
that of the native receptors. Our results show that the ecdysone sys-
tem allows expression to be tightly controlled, producing barely
detectable background levels and high signal-to-background ra-
tios. It also allowed us to develop assays that show long-term sta-
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FIG. 4. Antagonism by LY341495 of the DCG-IV and L-glutamate
stimulated calcium mobilization of cell lines 2q/o and 8q/o, respectively.
Cells were pretreated for 10 min with LY341495 over the indicated con-
centration ranges before a challenge with an EC80 concentration of ago-
nist. Inhibition curves were constructed from the percentage responses
pooled from 3 independent experiments performed in quadruplicate. Cal-
culated IC50 values are presented in Table 1.
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FIG. 5. Effect of various agonists on CAi2 + mobilization in cell line
8q/o expressing mGluR8 and the chimeric G protein Gαq/o. Agonists are
(S)-3,4-DCPG (; mGluR8 selective), + L-AP4 (+; group III selective),
L-CCG-I (; group II-III selective), RS-PPG (*; mGluR8 selective), L-
glutamate (), and quisqualate (; group I selective). Values are means ±
SEM of quadruplicate determinations from a typical experiment. (Inset)
Concentration-response curves (mean ± SEM, n = 3) for the effect of L-
glutamate on calcium mobilization using cell line 8q/o expressing
mGluR8 and the chimeric G protein Gαq/o, pretreated for 24 h in the ab-
sence () or presence () of ponasterone A (5 µM).
bility, showing both consistent EC50 values and RFUs even at high
passage numbers. Assay reproducibility was also good, and our
mGluR5 assay has a calculated Z′ value of 0.7, showing remark-
able across-plate uniformity. The combined use of the ecdysone
system and the chimeric G protein Gαq/o not only avoids receptor
desensitization and time- and passage-dependent receptor down-
regulation but also allowed us to use the same fluorescent assay
format for all mGlu receptors. Having a single assay format that
can be used to evaluate all mGluRs should accelerate both screen-
ing and counterscreening activities. Here, we present data from
representative receptors from each group, but the same approach
should be applicable to all mGlu receptors. To express hmGluR2
and hmGluR8, we employed 2 distinct strategies: In our 2q/o cell
line, the chimeric G protein was constitutively expressed, whereas
in our 8q/o cell line, the expression of the chimeric G protein was
inducible. Both strategies were successful, suggesting that over-
expression of a chimeric G protein is not particularly deleterious
for the cell. However, as the Gαq/o protein can couple to any Gαi/
Gαo-coupled cellular receptor, limiting its expression temporally
to that of its desired target should, at least in theory, reduce any
potentially undesired effects.
To date, there are very few reports of the ecdysone system being
used to express GPCRs. However, in 1 notable exception, different
5HT receptors were expressed using the Tet on and the ecdysone
systems; although the authors reported higher overall expression
levels with the Tet on system, the ecdysone system gave much
better induction ratios with effectively undetectable background
levels.37 Other groups have used the expression of reporter genes to
compare different inducible systems, and their results also demon-
strate that the ecdysone system produces very high induction ratios
with negligible background expression.38,39 Our results not only
show that the ecdysone system allows expression to be tightly
controlled but also demonstrate that the system can produce very
reproducible assays. We believe that the ecdysone system is an
excellent system for functional receptor studies and that it can
produce sufficiently robust assays to be used in screening cam-
paigns in which reproducibility and assay stability are of para-
mount importance.
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